ADCIST 10 MG

The database places Cisplatin in the setting of Broad range of solid tumors including bladder, lung, head and neck, ovarian, testicular, cervical and gastric cancers. Its pharmacological class is Platinum compound, while the treatment category is Chemotherapy; Platinum-Based Chemotherapy. Forms intra- and inter-strand DNA cross-links and disrupts DNA replication/transcription. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. The associated tumor types are Bladder; NSCLC; Head and Neck; Ovarian; Testicular; Cervical; Gastric. The regimen examples supplied for this medicine include BEP; DHAP; cisplatin + gemcitabine; cisplatin + pemetrexed; chemoradiation regimens; FOLFOX-like combinations are not standard cisplatin regimens. That list gives useful context because its role may change with the disease, treatment line, and combination partner. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. Any receptor, mutation, prior-treatment, or disease-state condition stated in the indication should be regarded as part of the treatment definition. Similar medicines may share a broad class without having the same target or clinical positioning, so the individual mechanism remains important. This entry is a reference summary rather than a prescribing protocol and contains no individualized dose or administration recommendation. Current regulatory labeling and disease-specific guidelines should be consulted for contemporary use.